Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E. Lucas N, et al. Among authors: duchmann m. Leukemia. 2019 Oct;33(10):2466-2480. doi: 10.1038/s41375-019-0447-3. Epub 2019 Mar 20. Leukemia. 2019. PMID: 30894665
[Management of myelodysplastic syndromes].
Duchmann M, Fenaux P, Cluzeau T. Duchmann M, et al. Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26. Bull Cancer. 2015. PMID: 26410692 Review. French.
CMML: Clinical and molecular aspects.
Itzykson R, Duchmann M, Lucas N, Solary E. Itzykson R, et al. Among authors: duchmann m. Int J Hematol. 2017 Jun;105(6):711-719. doi: 10.1007/s12185-017-2243-z. Epub 2017 Apr 28. Int J Hematol. 2017. PMID: 28455647 Review.
Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R. Duchmann M, et al. Blood Cancer J. 2017 May 12;7(5):e562. doi: 10.1038/bcj.2017.41. Blood Cancer J. 2017. PMID: 28498370 Free PMC article. No abstract available.
Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R. Duchmann M, et al. EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25. EBioMedicine. 2018. PMID: 29728305 Free PMC article. Clinical Trial.
Clinical update on hypomethylating agents.
Duchmann M, Itzykson R. Duchmann M, et al. Int J Hematol. 2019 Aug;110(2):161-169. doi: 10.1007/s12185-019-02651-9. Epub 2019 Apr 24. Int J Hematol. 2019. PMID: 31020568 Review.
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.
Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, Quentin S, Pasanisi J, Passet M, Rabian F, Rahmé R, Lengliné E, Raffoux E, Dhédin N, Sébert M, Maarek O, Raimbault A, Celli-Lebras K, Adès L, Fenaux P, Boissel N, Delhommeau F, Soulier J, Dombret H, Clappier E, Sujobert P, Itzykson R. Cerrano M, et al. Among authors: duchmann m. Leukemia. 2021 Mar;35(3):712-723. doi: 10.1038/s41375-020-0932-8. Epub 2020 Jun 24. Leukemia. 2021. PMID: 32581253
Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study.
Jestin M, Tarfi S, Duchmann M, Badaoui B, Freynet N, Tran Quang V, Sloma I, Droin N, Morabito M, Leclerc M, Maury S, Fenaux P, Solary E, Selimoglu-Buet D, Wagner-Ballon O; Groupe Francophone des Myélodysplasies (GFM). Jestin M, et al. Among authors: duchmann m. Leukemia. 2021 Mar;35(3):893-896. doi: 10.1038/s41375-020-0955-1. Epub 2020 Jul 20. Leukemia. 2021. PMID: 32684630 No abstract available.
Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
Willekens C, Rahme R, Duchmann M, Vidal V, Saada V, Broutin S, Delahousse J, Renneville A, Marceau A, Clappier E, Uzunov M, Rossignol J, Pascal L, Simon L, Micol JB, Pasquier F, Raffoux E, Preudhomme C, Quivoron C, Itzykson R, Penard-Lacronique V, Paci A, Fenaux P, Attar EC, Frattini M, Braun T, Ades L, De Botton S. Willekens C, et al. Among authors: duchmann m. Leuk Lymphoma. 2021 Feb;62(2):438-445. doi: 10.1080/10428194.2020.1832661. Epub 2020 Oct 12. Leuk Lymphoma. 2021. PMID: 33043739
27 results